Drugs / Tinostamustinein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04279938 | Sep 2018 → Mar 2020 | relapsed/refractory diffuse large B-cell lymphoma | Royal Marsden NHS Foundation Trust | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tinostamustinein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04279938 ↗ |
| Route | Intravenous | “Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles” NCT04279938 ↗ |